The role of automated cytometry in the new era of cancer immunotherapy.

  title={The role of automated cytometry in the new era of cancer immunotherapy.},
  author={Marco Danova and Martina Torchio and Giuditta Comolli and Andrea Sbrana and Andrea Antonuzzo and Giuliano Mazzini},
  journal={Molecular and clinical oncology},
  volume={9 4},
The introduction in the clinical practice of several new approaches to cancer immunotherapy has greatly increased the interest in analytical methodologies that can define the immunological profile of patients in the clinical setting. This requires huge effort to obtain reliable monitoring tools that could be used to improve the patient's clinical outcome. The clinical applications of flow cytometry (FCM) in oncology started with the measurement of DNA content for the evaluation of both ploidy… 

Recent advances in mass spectrometry based clinical proteomics: applications to cancer research

Improvements in MS-based clinical proteomics not only solidify their integral position in cancer research, but also accelerate the shift towards becoming a regular component of routine analysis and clinical practice.

Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery

Bioinformatics tools, in addition to histopathological assessment, immunological readouts from functional bioassays and deep T-cell ‘adaptome’ analyses, are expected to advance discovery and development of next-generation personalized precision medicine strategies to improve clinical outcomes in cancer.

Cancer immunotherapy and flow cytometry in immunotherapy monitoring

This study highlights the need to understand more fully the role of “cell reprograming” in the development of regenerative medicine and its role in wound healing.


The most commonly used methods for in vitro research in NSCLC (non-small cell lung cancer) based on testing the effects of new compounds to determine the degree of apoptosis, necrosis, cell proliferation as well as their significance are discussed.

A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology

The present review will highlight the importance of spatial transcriptomic and spatial proteomics analysis along with the joint use of other sequencing technologies and their implications in cancers and immune-oncology.

Full spectrum flow cytometry and mass cytometry: A 32‐marker panel comparison

A direct comparison of two technology platforms (MC and FSFC) using a 32‐marker flow cytometric immune monitoring panel that can identify all the previously described and anticipated immune subpopulations defined by this panel is reported.

Utilizing Flow Cytometry Effectively

Clinically, current uses for flow cytometry are primarily in hematologic malignancies and immunology, and research applications include a wide variety of uses including phenotyping, cell death and proliferation, cell signaling, fluorescence-activated cell sorting, and monitoring immune responses.

Adoptive immunotherapy via CD4+ versus CD8+ T cells

The benefits of adoptive immunotherapy mediated by CD8+ and CD4+ cells are discussed and the various type of T cells, source of T cell, and ex vivo cytokine growth factors for augmenting clinical efficacy of ACT are discussed.

Honokiol induces apoptotic cell death by oxidative burst and mitochondrial hyperpolarization of bladder cancer cells.

The results suggest that Honokiol induces apoptosis via the mitochondrial pathway and honokiol-containing traditional herbal remedies may have a potential clinical application in the treatment of bladder cancer.

A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

The focus here is narrow and on pathologic changes in the chaperome executed by enhancing the interaction strength between components of distinct chaperomes pathways, specifically between those of HSP90 and HSP70 pathways.



Clinical Applications of and Challenges in Single-Cell Analysis of Circulating Tumor Cells.

The fundamental principles of CTC isolation and single-cell sequencing are reviewed and recent progress in their application in both basic research and clinical fields are discussed and the current challenges are described.

Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors.

Isolation of rare circulating tumor cells in cancer patients: technical aspects and clinical implications

The techniques currently utilized for isolation and characterization of CTCs are reviewed and their potential utility in clinical oncology is discussed focusing on the future perspectives in this field.

Flow cytometric analysis of circulating endothelial cells and endothelial progenitors for clinical purposes in oncology: A critical evaluation.

A critical review of the issues that limit the comparability of results of the most significant studies employing FCM for CEC and/or EPC detection in patients with cancer is presented.

Systems immune monitoring in cancer therapy.

Implementing liquid biopsies into clinical decision making for cancer immunotherapy

This article summarizes the knowledge of the well-known liquid material in a new context as liquid biopsy and focuses on collection and assay requirements for the analysis and the technical developments that allow the implementation of different high-throughput assays to detect alterations at the genetic and immunologic level.

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

High-dimensional single-cell mass cytometry and a bioinformatics pipeline are used for the in-depth characterization of the immune cell subsets in the peripheral blood of patients with stage IV melanoma before and after 12 weeks of anti-PD-1 immunotherapy to propose that the frequency of monocytes in PBMCs may serve in clinical decision support.

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

The concept of the tumor immunity continuum is proposed as a framework for developing rational combination strategies for anticancer immune therapies based on current understanding of tumor and circulating pharmacodynamic correlates of immune modulation.

Prognostic relevance of DNA flow cytometry in breast cancer revisited: The 25-year experience of the Portuguese Institute of Oncology of Lisbon.

Data from Portuguese Institute of Oncology of Lisbon reinforces the clinical importance and utility of DNA flow cytometric analysis, particularly DNA ploidy, in the prognostic assessment and therapeutic planning for patients with breast cancer.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

The current status of emerging biomarkers for immune checkpoint blockade therapy is focused on and novel technologies as well as high dimensional data analysis platforms that will be pivotal for future biomarker research are discussed.